<DOC>
	<DOCNO>NCT01204775</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability , Saxagliptin pediatric patient type 2 diabetes .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Tolerability , Pharmacokinetics Saxagliptin Monotherapy Pediatric Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female patient eligible 10 year age , 17 year 32 week age time randomization , diagnose type 2 diabetes prior study enrollment . HbA1c ≥7.0 % ≤10.5 % Body weight ≥ 30 kg . BMI &gt; 85th percentile Age Reproductive Status ) Women childbearing potential ( WOCBP ) men must use acceptable method contraception avoid pregnancy throughout study 4 week last dose investigational product manner risk pregnancy minimize . The decision appropriate method prevent pregnancy determine discussion investigator study subject . b ) WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start investigational product . c ) Women must breastfeed . ) Sexually active fertile men must use effective birth control partner WOCBP . 1 . Target Disease Exceptions ) Current use follow medication treatment diabetes , use within specify timeframe prior screen study : ) Six month : insulin . ii ) Four month : thiazolidinediones . iii ) Two month : antidiabetic treatment iv ) Any previous use DPP4inhibitor and/or incretin mimetics b ) Current use prescription nonprescription weight loss drug use within 3 month screen . 2 . Medical History Concurrent Diseases ) Significant comorbidity , opinion investigator would preclude participation study ( eg , current treatment cancer ) . b ) Previous diagnosis monogenic etiology type 2 diabetes MODY ( maturity onset diabetes youth ) secondary diabetes ( steroid use , Cushing 's disease , acromegaly ) . c ) Significant cardiovascular history . ) History hemoglobinopathy ( sickle cell anemia thalassemia , sideroblastic anemia ) . e ) History unstable rapidly progressive renal disease . f ) History alcohol drug abuse . g ) Psychiatric cognitive disorder , opinion investigator , limit patient 's ability comply study medication monitoring . h ) Administration study drug participation clinical research trial within 30 day plan enrollment study ( long period dictate local regulatory authority ) . ) Any condition , investigator 's opinion may render subject unable complete study may pose significant risk subject . j ) Immunocompromised individual subject undergo organ transplantation subject diagnose human immunodeficiency virus . k ) Subjects commercial weight loss program ongoing weight loss , intensive exercise program . 3 . Physical Laboratory Test Findings ) Fasting plasma glucose ( FPG ) &gt; 255 mg/dL ( 14.2 mmol/L ) screen exclude patient . b ) Diabetic ketoacidosis ( DKA ) within 6 month study entr1 ) Target Disease Exceptions ) Current use follow medication : ) Six month : insulin . ii ) Four month : thiazolidinediones . iii ) Two month : antidiabetic treatment iv ) Any previous use DPP4inhibitor and/or incretin mimetics b ) Current use prescription nonprescription weight loss drug use within 3 month screen . 2 ) Medical History Concurrent Diseases ) Significant comorbidity , opinion investigator would preclude participation study ( eg , current treatment cancer ) . b ) Previous diagnosis monogenic etiology type 2 diabetes MODY ( maturity onset diabetes youth ) secondary diabetes ( steroid use , Cushing 's disease , acromegaly ) . c ) Significant cardiovascular history . ) History hemoglobinopathy ( sickle cell anemia thalassemia , sideroblastic anemia ) . e ) History unstable rapidly progressive renal disease . f ) History alcohol drug abuse . g ) Psychiatric cognitive disorder , opinion investigator , limit patient 's ability comply study medication monitoring . h ) Administration study drug participation clinical research trial within 30 day plan enrollment study ( long period dictate local regulatory authority ) . ) Any condition , investigator 's opinion may render subject unable complete study may pose significant risk subject . j ) Immunocompromised individual subject undergo organ transplantation subject diagnose human immunodeficiency virus . k ) Subjects commercial weight loss program ongoing weight loss , intensive exercise program . 3 ) Physical Laboratory Test Findings 1 . Fasting plasma glucose ( FPG ) &gt; 255 mg/dL ( 14.2 mmol/L ) screen 2 . Diabetic ketoacidosis ( DKA ) within 6 month study entry ( DKA occur present sign type 2 diabetes youth ) . 3 . Abnormal renal function , define abnormal creatinine clearance rate determine Schwartz Formula Exclusion study participation apply calculate glomerular filtration rate &lt; 80 mL/min/1.73m2 ( 1.33 mL/s ) . ) Presence one following : antibody glutamic acid decarboxylase ( GAD ) , islet cell autoantibody ( ICA ) , protein tyrosine phosphataselike protein antibody ( IA2 ) . e ) Active liver disease and/or significant abnormal liver function define Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal , and/or serum total bilirubin &gt; 2.0 mg/dL . f ) History positive serologic evidence current infectious liver disease include antiHAV ( IgM ) , HbsAg , antiHCV . Patients may isolate positive anti HBs may include . g ) Anemia etiology define hemoglobin ≤ 10.7 g/dL ( 107 g/L ) females ≤ 11.3 g/dL ( 113 g/L ) male . h ) An abnormal TSH value screen evaluate free T4 . Subjects abnormal T4 exclude . ) Creatinine kinase ( CK ) ≥ 3 X ULN . j ) Clinically significant ( CS ) abnormalities prerandomization laboratory analyse ECG , investigator 's opinion , would preclude randomization . 4 ) Allergies Adverse Drug Reaction 1 . Subjects contraindication therapy outline Saxagliptin Investigator Brochure local metformin package insert . 2 . Subjects know contraindication DPPIV therapy . 5 ) Prohibited Therapies and/or Medications ) Steroid use exclusion : ) Excluded : use oral parenteral corticosteroid within 3 month ii ) Allowed : inhaled corticosteroid asthma , topical corticosteroid limit minor surface area . b ) Use antihyperglycemic medication ( metformin insulin applicable glycemic rescue ) entry placebo leadin period . c ) Prior treatment saxagliptin . ) Subjects take prohibit medication list Section 3.4 . Subjects stop prohibit medication prior study participation must undergo appropriate wash period visit 1. e ) Diabetes treatment use weight loss medication f ) Current treatment potent CYP3A4/5 inhibitor ( country dose adjustment would require saxagliptin label ) . 6 ) Sex Reproductive Status ) Pregnant , positive serum pregnancy test , plan become pregnant clinical trial , breastfeed . 7 ) Other Exclusion Criteria 1 . Prisoners subject involuntarily incarcerate . 2 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness . 3 . Employees BMS , AstraZeneca ( AZ ) , relatives .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>